CANC Among Its Peers
End-of-day Nov 19, 2026 · 1 ETFs by 1Y
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −1.4% | −7.0% | −7.8% | −14.1% | +10.3% | +13.5% | +73.4% | — | — | +61.9% |
| S&P 500 · VOO | −2.0% | −5.5% | −7.4% | −6.3% | +5.8% | +9.7% | +65.8% | +65.5% | +290.0% | — |
$63 of every $1,000 in CANC is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S | Healthcare | 6.35% | $634.63 | 249K | $12.7M |
| 2 | RVMDRevolution Medicines | Healthcare | 5.48% | $548.47 | 69K | $11.0M |
| 3 | LLYELI Lilly | Healthcare | 5.19% | $518.56 | 7,504 | $10.4M |
| 4 | MRKMerck | Healthcare | 4.46% | $446.48 | 65K | $8.9M |
| 5 | ONCBeone Medicines | Healthcare | 4.44% | $443.99 | 22K | $8.9M |
| 6 | COGTCogent Biosciences | Healthcare | 4.43% | $442.75 | 319K | $8.9M |
| 7 | EXELExelixis | Healthcare | 3.91% | $391.10 | 115K | $7.8M |
| 8 | NOVN.SWNovartis AG | Healthcare | 3.82% | $381.98 | 49K | $7.6M |
| 9 | ABBVAbbvie | Healthcare | 3.47% | $346.90 | 24K | $6.9M |
| 10 | BBIOBridgebio Pharma | Healthcare | 3.37% | $336.93 | 86K | $6.7M |
| 11 | RHHBYRoche AG | Healthcare | 3.35% | $335.06 | 113K | $6.7M |
| 12 | CGONCG Oncology | Healthcare | 3.28% | $327.73 | 82K | $6.6M |
| 13 | HALOHalozyme Therapeutics | Healthcare | 3.05% | $304.60 | 64K | $6.1M |
| 14 | ELVNEnliven Therapeutics | Healthcare | 2.68% | $268.28 | 120K | $5.4M |
| 15 | BMYBristol-myers Squibb | Healthcare | 2.51% | $251.23 | 84K | $5.0M |
CANC has no close peers in our data yet: […]
No peers with a full year of prices to rank against yet.
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S | 6.35% |
| 2 | RVMD | Revolution Medicines | 5.48% |
| 3 | LLY | ELI Lilly & | 5.19% |
| 4 | MRK | Merck & | 4.46% |
| 5 | ONC | Beone Medicines | 4.44% |
| 6 | COGT | Cogent Biosciences | 4.43% |
| 7 | EXEL | Exelixis | 3.91% |
| 8 | NOVN.SW | Novartis AG | 3.82% |
| 9 | ABBV | Abbvie | 3.47% |
| 10 | BBIO | Bridgebio Pharma | 3.37% |
| Fund | Sharpe | Sortino | Volatility | Max DD | Beta | Fee / $10k |
|---|---|---|---|---|---|---|
| CANC | 0.48 | 0.73 | 24.3% | −15.3% | 0.80 | $99 |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 12, 2024 | $0.73 |
| Dec 13, 2023 | Dec 15, 2023 | $0.15 |